Loading
Thyroid Cancer Diagnosis and Treatment / Thyroid Disorders and Treatments · Journal article
Endocrines · September 7, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes evidence that 3,5-diiodothyronine (3,5-T2), a thyroid hormone metabolite, enhances mitochondrial respiration and oxidative metabolism in animal models, particularly in liver and skeletal muscle. However, the review explicitly identifies major translational gaps: most data come from animal studies using pharmacologic doses, endogenous human physiology and molecular targets remain incompletely understood, HPT axis suppression has been observed with exogenous 3,5-T2, and circulating 3,5-T2 measurement remains unreliable, precluding clinical translation and therapeutic use.
Journal article.
Experimental studies suggest 3,5-T2 enhances mitochondrial respiration, fatty acid oxidation, oxidative phosphorylation, and metabolic efficiency in metabolically active tissues. 3,5-T2 has generated interest in potential treatment of metabolic disorders including metabolic dysfunction-associated steatotic liver disease, obesity, and insulin resistance. Most available data derive from animal studies using pharmacologic doses; endogenous physiology of 3,5-T2 in humans remains incompletely understood.
No human clinical trial data, efficacy estimates, or safety signals from human studies presented. Most available data derive from animal studies using pharmacologic doses; endogenous physiology of 3,5-T2 in humans remains incompletely understood.
Clinicians should recognize that 3,5-T2 remains a research molecule without established human dosing, efficacy, safety profile, or reliable biomarkers. This review does not support clinical use and emphasizes that key mechanistic and translational studies must precede any consideration for human therapeutic application.
This is a narrative review synthesizing experimental animal studies and emerging translational work on 3,5-T2; it raises mechanistic questions and identifies knowledge gaps rather than reporting a definitive clinical result or trial outcome.
Clinicians should recognize that 3,5-T2 remains a research molecule without established human dosing, efficacy, safety profile, or reliable biomarkers. This review does not support clinical use and emphasizes that key mechanistic and translational studies must precede any consideration for human therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Thyroid hormone physiology has traditionally been understood through the hypothalamic–pituitary–thyroid (HPT) axis and the genomic actions of triiodothyronine (T3). However, advances in thyroid hormone biology have expanded this classical paradigm, demonstrating that thyroid hormone signaling is regulated through a coordinated network involving tissue-specific deiodination, specialized membrane transporters, genomic and non-genomic signaling pathways, and mitochondrial regulation of cellular bioenergetics. Among the iodothyronine metabolites generated through thyroid hormone metabolism, 3,5-diiodothyronine (3,5-T2) has emerged as one of the most extensively investigated because of its reported ability to rapidly influence mitochondrial respiration, oxidative metabolism, and energy expenditure. Experimental studies suggest that 3,5-T2 enhances mitochondrial respiration, fatty acid oxidation, oxidative phosphorylation, and metabolic efficiency, particularly in metabolically active tissues such as liver and skeletal muscle. These findings have generated considerable interest in the potential role of 3,5-T2 in metabolic disorders characterized by mitochondrial dysfunction, including metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and insulin resistance. However, important translational challenges remain. Most available data derive from animal studies using pharmacologic doses, while the endogenous physiology of 3,5-T2 in humans, its molecular targets, tissue-specific regulation, and long-term endocrine effects remain incompletely understood. In addition, evidence of hypothalamic–pituitary–thyroid axis suppression following exogenous 3,5-T2 administration and limitations in accurately measuring circulating 3,5-T2 continue to complicate clinical translation. This review critically evaluates the emerging biology of 3,5-diiodothyronine, integrating current evidence regarding its biosynthesis, mechanisms of thyroid hormone signaling, mitochondrial actions, metabolic effects, translational challenges, and future research priorities. By synthesizing findings from primary experimental studies and emerging translational investigations, this review places 3,5-T2 within the broader framework of contemporary thyroid hormone biology while highlighting key knowledge gaps that must be addressed before its physiological and therapeutic significance can be fully established.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.